undamentalytics Newsletter
Sign in

Arcadia Biosciences, Inc. income statement

In fiscal 2025, Arcadia Biosciences, Inc. reported revenue of $4.9m, down 3.7% on the year before, operating income of −$2.5m (a -51.5% margin) and net income of −$2.3m, or −$1.71 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue7534118774555
Cost of revenue——————5962333
Gross profit——————3−212222
Research and development1099767842000—
Selling, general and administrative10111211121416231581075
Operating income−15−16−19−14−17−19−13−36−14−6−4−3−4
Interest expense1311—000—————
Net interest income———————−001100
Income before tax−18−18−20−16−13−29−6−16−11−5−4−2—
Income tax000000−000000—
Net income−18−18−20−16−13−29−5−15−15−14−7−2−11
Diluted EPS−$4284.00−$292.00−$177.00−$145.60−$71.60−$90.60−$9.40−$13.78−$12.82−$11.29−$5.17−$1.71−$5.70
Diluted shares (average)—71m111m————1m1m1m1m1m2m
EBITDA−15−15−18−14−17−19−12−35−14−6−4−2−4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CBUS vs RKDAPFAI vs RKDARKDA vs WFCF

More: Agricultural Products & Services stocks compared, Consumer Staples sector, rankings of US companies

Figures from Arcadia Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcadia Biosciences, Inc.